Veru (STU:FMW) EBIT per Share : €-0.30 (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Veru EBIT per Share?

Veru's EBIT per Share for the three months ended in Mar. 2024 was €-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.30.

During the past 3 years, the average EBIT per Share Growth Rate was -382.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was -49.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Veru's EBIT per Share or its related term are showing as below:

STU:FMW' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -382.7 Med: 16.1 Max: 192
Current: -382.7

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Veru was 192.00% per year. The lowest was -382.70% per year. And the median was 16.10% per year.

STU:FMW's 3-Year EBIT Growth Rate is ranked worse than
99.69% of 1299 companies
in the Biotechnology industry
Industry Median: 3.4 vs STU:FMW: -382.70

Veru's EBIT for the three months ended in Mar. 2024 was €-8.92 Mil.

Veru EBIT per Share Historical Data

The historical data trend for Veru's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru EBIT per Share Chart

Veru Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT per Share

Get a 7-Day Free Trial

-0.11

-0.20

0.09

-1.00

Veru Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.38	-0.06	-0.11	-0.08	-0.06

Veru EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Veru's EBIT per Share for the fiscal year that ended in Sep. 2023 is calculated as

	EBIT per Share		(A: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-84.56	/	84.973
=	-1.00

Veru's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.923	/	146.381
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.30

Veru (STU:FMW) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Veru EBIT per Share Related Terms

Thank you for viewing the detailed overview of Veru's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru (STU:FMW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

VERU:USA FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru (STU:FMW) Headlines

No Headlines